0001209191-21-018154.txt : 20210305
0001209191-21-018154.hdr.sgml : 20210305
20210305153213
ACCESSION NUMBER: 0001209191-21-018154
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210303
FILED AS OF DATE: 20210305
DATE AS OF CHANGE: 20210305
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Dasu Badri N
CENTRAL INDEX KEY: 0001310803
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35068
FILM NUMBER: 21718250
MAIL ADDRESS:
STREET 1: C/O ACELRX PHARMACEUTICALS, INC.
STREET 2: 351 GALVESTON DRIVE
CITY: REDWOOD CITY
STATE: CA
ZIP: 94063
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ACELRX PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001427925
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 351 GALVESTON DRIVE
CITY: REDWOOD CITY
STATE: CA
ZIP: 94063
BUSINESS PHONE: 650-216-3500
MAIL ADDRESS:
STREET 1: 351 GALVESTON DRIVE
CITY: REDWOOD CITY
STATE: CA
ZIP: 94063
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-03-03
0
0001427925
ACELRX PHARMACEUTICALS INC
ACRX
0001310803
Dasu Badri N
C/O ACELRX PHARMACEUTICALS, INC.
351 GALVESTON DRIVE
REDWOOD CITY
CA
94063
0
1
0
0
Chief Engineering Officer
Common Stock
2021-03-03
4
A
0
50000
0.00
A
204757
D
Stock Option (Right to Buy)
1.88
2021-03-03
4
A
0
100000
0.00
A
2031-03-03
Common Stock
100000
100000
D
Stock Option (Right to Buy)
1.88
2021-03-03
4
A
0
50000
0.00
A
2031-03-03
Common Stock
50000
50000
D
Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
The restricted stock units shall vest in three equal consecutive annual installments on March 3, 2022, March 3, 2023 and March 3, 2024.
Balance includes the acquisition of 10,000 shares of Common Stock through the Company's Employee Stock Purchase Plan.
The shares subject to the option vest as follows: 25% of the shares subject to the option vest on the 12 month anniversary of the date of grant and the remaining shares subject to the option vest on an equal monthly basis over the following 36 months.
On March 3, 2021, the Reporting Person was granted performance options subject to the satisfaction of share price targets over a performance period from March 3, 2021 to December 31, 2024 (the "Performance Period"), as determined by the Compensation Committee (the "Committee") of the Company's Board of Directors.
The performance options shall be earned as follows: (i) 33% of the performance options if the Company's average closing stock price measured over a period of thirty consecutive trading days within the Performance Period equals or exceeds $4.00, (ii) an additional 33% of the performance options if the Company's average closing stock price measured over a period of thirty consecutive trading days within the Performance Period equals or exceeds $5.00, and (iii) 34% of the performance options if the Company's average closing stock price measured over a period of thirty consecutive trading days within the Performance Period equals or exceeds $6.00. Once earned, the performance options will vest on the one-year anniversary of the date on which the Committee certified achievement of an applicable price target, so long as the reporting person remains in continuous service through such applicable vesting date.
/s/ Martha Adler, Attorney-In-Fact
2021-03-05